Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) reported on Wednesday the receipt of final approval from the US Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Mycolog II Cream (nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/gram).
In the Q4 2017, the company is expected to introduce its AB Rated generic version of Mycolog II Cream in the commercial market in the US.
The company said the Mycolog II Cream is indicated for the treatment of cutaneous candidiasis.
For the 12 months ended June 2017, the annual market sales for Mycolog II Cream was approximately USD93m, according to the company.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream